Vitro Biopharma, Inc. financial data

Location
Denver, CO
Fiscal year end
31 October
Latest financial report
10-K - Q3 2025 - 13 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.3% % -72%
Quick Ratio 1.4% % -23%
Debt-to-equity -138% % 28%
Return On Assets -234% % -57%
Operating Margin -244% % 50%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4,517,651 shares 1.3%
Common Stock, Shares, Outstanding 4,460,535 shares 0%
Entity Public Float $0 USD
Common Stock, Value, Issued $4,460 USD 0%
Weighted Average Number of Shares Outstanding, Basic 4,460,535 shares 0.03%
Weighted Average Number of Shares Outstanding, Diluted 4,460,535 shares 0.03%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $2,056,818 USD 11%
Revenue from Contract with Customer, Excluding Assessed Tax $2,056,818 USD 11%
Research and Development Expense $533,028 USD -14%
Operating Income (Loss) $5,023,089 USD 45%
Net Income (Loss) Attributable to Parent $10,851,802 USD -9.9%
Earnings Per Share, Basic -2.44 USD/shares -10%
Earnings Per Share, Diluted -2.44 USD/shares -10%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current $206,292 USD 72%
Inventory, Net $134,833 USD 17%
Assets, Current $862,103 USD -12%
Property, Plant and Equipment, Net $42,168 USD -70%
Operating Lease, Right-of-Use Asset $360,681 USD -25%
Intangible Assets, Net (Excluding Goodwill) $327,608 USD -8.5%
Goodwill $3,171,581 USD 0%
Other Assets, Noncurrent $8,438 USD 0%
Assets $4,929,210 USD -5.7%
Accounts Payable, Current $2,442,630 USD 11%
Accrued Liabilities, Current $1,863,630 USD 17%
Liabilities, Current $5,679,141 USD -44%
Operating Lease, Liability, Noncurrent $223,868 USD -38%
Liabilities $21,262,877 USD 49%
Retained Earnings (Accumulated Deficit) $48,801,495 USD -29%
Stockholders' Equity Attributable to Parent $16,333,667 USD -81%
Liabilities and Equity $4,929,210 USD -5.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $428,336 USD 64%
Net Cash Provided by (Used in) Financing Activities $29,226 USD -101%
Net Cash Provided by (Used in) Investing Activities $74 USD 85%
Common Stock, Shares Authorized 19,230,770 shares 0%
Common Stock, Shares, Issued 4,460,535 shares 0%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $604,183 USD 5.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities $4,220 USD -14%
Deferred Tax Assets, Valuation Allowance $9,840,000 USD 32%
Deferred Tax Assets, Gross $9,840,000 USD 32%
Operating Lease, Liability $360,681 USD 4.2%
Depreciation $102,555 USD -43%
Lessee, Operating Lease, Liability, to be Paid $431,993 USD -28%
Property, Plant and Equipment, Gross $1,064,935 USD 0.49%
Operating Lease, Liability, Current $136,813 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Two $84,609 USD -49%
Lessee, Operating Lease, Liability, to be Paid, Year One $166,760 USD 1.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $71,312 USD -71%
Lessee, Operating Lease, Liability, to be Paid, Year Three $67,734 USD -20%
Deferred Tax Assets, Operating Loss Carryforwards $5,286,000 USD 16%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $67,734 USD 0%
Operating Lease, Payments $40,757 USD -28%
Additional Paid in Capital $32,547,333 USD 12%
Amortization of Intangible Assets $30,476 USD -52%
Interest Expense $2,505,480 USD 1345%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%